Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

32.82

Mkt cap

1.9B

Volume

479K

High

33.05

P/E Ratio

13.04

52-wk high

41.61

Low

32.06

Div yield

N/A

52-wk low

28.14

Needham analyst Ami Fadia reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $50 price target. This reaffirms the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 5:24 pm

Harmony Biosciences' stock is trading higher following the announcement of an exclusive licensing agreement with Bioprojet for TPM-1116, aimed at treating narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:54 pm

Harmony Biosciences (HRMY) has entered into an exclusive licensing agreement with Bioprojet to develop and commercialize TPM-1116, a promising oral orexin-2 receptor agonist for treating narcolepsy and other sleep/wake disorders. Harmony will pay Bioprojet $25.5 million upfront, with potential future payments totaling up to $367.5 million based on development, regulatory, and sales milestones, plus mid-teen royalties on sales. This agreement aims to bolster Harmony's position in the sleep/wake disorder market by leveraging the potential of TPM-1116 to offer a best-in-class clinical profile.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:07 pm

Needham analyst Ami Fadia reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 10:24 am

Harmony Biosciences (NASDAQ:HRMY) was analyzed by 8 financial analysts, showing a mix of bullish to bearish sentiments. Recent ratings indicate a shift towards a more cautious outlook, with the average 12-month price target set at $42.62, reflecting an 11.42% increase from the previous target. Analyst actions vary, with some maintaining their ratings while others adjust their price targets. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown strong financial health with a notable revenue growth rate of 31.26%, a net margin of 15.8%, and an exceptional ROE of 5.61%.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 4:00 pm

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 2:26 pm

Mizuho analyst Graig Suvannavejh maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) but lowers the price target from $42 to $40.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 3:43 pm

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $49 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 5:20 pm

Needham analyst Ami Fadia maintains a Buy rating on Harmony Biosciences (NASDAQ:HRMY) but lowers the price target from $53 to $50.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 10:44 am

Analyst ratings for Harmony Biosciences (NASDAQ:HRMY) show mixed sentiments with a recent shift towards bullishness. The average 12-month price target has increased by 31.9% to $38.25. Analysts from Needham, Mizuho, Goldman Sachs, and B of A Securities have updated their ratings and price targets, reflecting changes in market conditions and company performance. Harmony Biosciences, a commercial-stage pharmaceutical company, has shown remarkable financial health with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 4:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.